| Autor: |
Holmström MO; holmeren1@yahoo.dk., Klausen U, Jørgensen NG, Holmberg S, Grauslund J, Met Ö, Svane IM, Pedersen LM, Knudsen LM, Hasselbalch HC, Andersen MH |
| Jazyk: |
dánština |
| Zdroj: |
Ugeskrift for laeger [Ugeskr Laeger] 2019 Mar 04; Vol. 181 (10). |
| Abstrakt: |
Cancer immune therapy is now used routinely for the treatment of several solid malignancies, albeit just recently having entered the clinic for treatment of haematological malignancies. Several studies demonstrate that cancer immune therapy is a promising treatment modality for the latter. Especially treatment with chimeric antigen receptor T cells for acute lymphoblastic leukaemia and lymphoma is promising. Other promising treatment modalities are immune check point inhibitors for both lymphoid and myeloid malignancies, as well as therapeutic cancer vaccination targeting tumour antigens. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
